RSV (respiratory syncytial virus) is a common virus that can cause upper and lower respiratory tract infection, particularly in young infants and older adults. Symptoms range from mild cold-like symptoms to severe conditions such as bronchiolitis and pneumonia.
The virus is highly contagious and spreads through respiratory droplets when an infected person coughs or sneezes.
Pregnant women: a single dose of Abrysvo® is recommended for use in pregnant women at 28–36 weeks gestation to protect their newborn infant. This is provided free on the National Immunisation Program.
Older adults: a single dose of RSV vaccine (either Abrysvo® or Arexvy®) is recommended to protect all people aged ≥75 years, Aboriginal and Torres Strait Islander people aged ≥60 years, and people with medical risk factors for severe RSV disease aged ≥60 years. A private prescription is required.
Infants: a single dose of Beyfortus™ (nirsevimab) is recommended before their 1st RSV season in young infants whose mothers did not receive RSV vaccine at least 2 weeks before delivery, and in young infants who are at increased risk of severe RSV disease, regardless of their mother’s vaccination status.
Children up to 24 months of age who have medical risk factors for severe RSV disease in their 2nd RSV season. The dose of Beyfortus™ for older children entering their 2nd RSV season is 200 mg, given as 2 intramuscular injections (2 × 1 mL of the 100 mg/mL formulation) at 2 different sites (preferably separate limbs, or else separated by 2.5 cm) during the same visit.
Immunisation Weekly Update: Federal ministers and national media react to falling vaccination rates Be mindful of measles before and after Hajj COVID-19 vaccine update and new resource Flu Vaccine Updates ‘Possible but rare’ RSV vaccine risk First Nations maternal vaccinations poster Federal ministers and national media react to falling vaccination…
Immunisation Weekly Update: CESPHN seeking Immunisation Working Group clinical representatives Lunch and Learn: Measles awareness and prevention in 2025 Concerns rise as vaccination rates continue to fall The latest influenza vaccination coverage data Access to existing Q Fever statements in the Q Fever Register to end 30 June 2025 Have…
Immunisation Weekly Update: Lunch and Learn: Measles awareness and prevention in 2025 Australia on track for record number of flu cases Free SMS recall – 2025 Quality Improvement programs Large-scale revamp of Handbook immunocompromised chapter In case you missed it… Beyfortus™ (nirsevimab) eligibility expansion Access to the Australian Immunisation Register…
Immunisation Weekly Update: Lunch and Learn: Measles awareness and prevention in 2025 New vaccination resources released Immunisation Handbook chapters updated Pharmacist Vaccination Standards updated Mpox disinformation corrected by experts New report on COVID-19 health impacts History of immunisation in Australia resource updated Lunch and Learn: Measles awareness and prevention in…
Immunisation Weekly Update: Updates to NSW Pharmacist Vaccination Standards Free ‘RSV Protection for Infants’ modules Updated vaccine co-administration resource Report Q fever vaccination records before 30 June Flu vaccine orders and updates Your experience matters: Have your say on vaccine storage Respiratory Surveillance Report Updates to NSW Pharmacist Vaccination Standards…